» Articles » PMID: 10051504

Transforming Growth Factor Beta1 Induces the Expression of Alpha1(I) Procollagen MRNA by a Hydrogen Peroxide-C/EBPbeta-dependent Mechanism in Rat Hepatic Stellate Cells

Overview
Journal Hepatology
Specialty Gastroenterology
Date 1999 Mar 3
PMID 10051504
Citations 74
Authors
Affiliations
Soon will be listed here.
Abstract

Oxidative stress plays a key role in liver fibrosis. Both inflammatory cells and activated Kupffer cells produce H2O2, an oxidant involved in the activation of hepatic stellate cells (HSC). Increased production of reactive oxygen intermediates (ROIs) in fibrotic livers is associated in part with the up-regulation of transforming growth factor beta (TGF-beta), and this cytokine enhances collagen production by cultured HSC. However, the possible link between oxidative stress and the molecular mechanisms by which TGF-beta induces collagen gene expression in HSC remains to be elucidated. To address this question, we investigated whether H2O2 is a mediator of TGF-beta-elicited alpha1(I) collagen gene (col1a1) up-regulation. We demonstrated that TGF-beta induces the accumulation of H2O2, and that this oxidant is, in turn, directly involved in up-regulating the expression of the col1a1 gene. While the addition of H2O2 to HSC induced the expression of alpha1(I) procollagen mRNA, catalase, an H2O2 enzyme scavenger, abrogated TGF-beta-mediated col1a1 gene up-regulation. We transfected HSC with chimeric plasmids driven by different segments of the mouse col1a1 promoter and mapped a cis-acting element (-370 to -344) essential for TGF-beta responsiveness. We further showed that TGF-beta induced the activation and binding of a C/EBPbeta-containing transcriptional complex to this sequence, an effect that was also mimicked by the addition of H2O2. Taken together, these data demonstrate a direct connection between TGF-beta-mediated accumulation of H2O2 and the up-regulation of col1a1 gene in HSC.

Citing Articles

Metabolism of hepatic stellate cells in chronic liver diseases: emerging molecular and therapeutic interventions.

Yan M, Cui Y, Xiang Q Theranostics. 2025; 15(5):1715-1740.

PMID: 39897543 PMC: 11780521. DOI: 10.7150/thno.106597.


Macronutrient Modulation in Metabolic Dysfunction-Associated Steatotic Liver Disease-the Molecular Role of Fatty Acids compared with Sugars in Human Metabolism and Disease Progression.

Mullin S, Kelly A, Ni Chathail M, Norris S, Shannon C, Roche H Adv Nutr. 2025; 16(3):100375.

PMID: 39842721 PMC: 11849631. DOI: 10.1016/j.advnut.2025.100375.


A new opportunity for N-acetylcysteine. An outline of its classic antioxidant effects and its pharmacological potential as an epigenetic modulator in liver diseases treatment.

Galicia-Moreno M, Monroy-Ramirez H, Caloca-Camarena F, Arceo-Orozco S, Muriel P, Sandoval-Rodriguez A Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39436429 DOI: 10.1007/s00210-024-03539-0.


CCAAT/Enhancer-Binding Proteins in Fibrosis: Complex Roles Beyond Conventional Understanding.

Wang L, Feng J, Deng Y, Yang Q, Wei Q, Ye D Research (Wash D C). 2022; 2022:9891689.

PMID: 36299447 PMC: 9575473. DOI: 10.34133/2022/9891689.


NOX as a Therapeutic Target in Liver Disease.

Matuz-Mares D, Vazquez-Meza H, Vilchis-Landeros M Antioxidants (Basel). 2022; 11(10).

PMID: 36290761 PMC: 9598239. DOI: 10.3390/antiox11102038.